Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01370525 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Esomeprazole in Patients With Frequent Heartburn
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 340
- Enrollment target
NCT01370525: Completed Phase 3 study, sponsored by AstraZeneca.
NCT01370525 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 340 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01370525, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 340 participants
- Enrollment target
Study Summary
This study will investigate the efficacy of esomeprazole 20 mg once a day in the treatment of frequent heartburn
Interventions
- DRUG Esomeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2011-08 |
| Est. Completion | 2011-10 |
| Phase | Phase 3 |
What the finished NCT01370525 record still lists
NCT01370525 is an interventional study that assigns participants to a tested intervention. The registered 340 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 1 intervention - of which Esomeprazole is the first listed.
NCT01370525 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01370525 about?
NCT01370525 is a clinical study titled "Efficacy of Esomeprazole in Patients With Frequent Heartburn". This study will investigate the efficacy of esomeprazole 20 mg once a day in the treatment of frequent heartburn
What is the current status of trial NCT01370525?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 340 participants. The study started on 2011-08. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01370525?
The interventions under investigation include: Esomeprazole (DRUG).
Who is sponsoring clinical trial NCT01370525?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01370525's enrollment target sits among peer trials
340 1053rd of 2000 higher than 945 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
- NCT04545424 · 340 participants · Phase 2
Trial of Therapeutic Hypothermia in Patients With ARDS
- NCT04806958 · 340 participants · NA
The PulsePoint Study
- NCT05323409 · 340 participants · NA
Improving Comprehensive Care of Cancer Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia